We are thrilled to share BioCryst Pharmaceutical’s big announcement: Health Canada has approved their oral, once-daily ORLADEYO® (berotralstat) for the routine prevention of HAE attacks in patients 12 years and older. Please CLICK HERE for their press release.

HAE patients in Canada are one step closer to gaining access to this oral treatment.